Surgical considerations in patients receiving neoadjuvant systemic therapy

Future Oncology

Volumn 8, Issue 3, 2012, Pages 239-250

  Chawla, Akhil ^a   Hunt, Kelly K ^b   Mittendorf, Elizabeth A ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

breast cancer; breast conserving therapy; neoadjuvant chemotherapy; sentinel lymph node dissection

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL DECISION MAKING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REGIMEN; EXTERNAL BEAM RADIOTHERAPY; FALSE POSITIVE RESULT; FOLLOW UP; HAZARD RATIO; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SATISFACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; TREATMENT FAILURE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; META-ANALYSIS AS TOPIC; NEOADJUVANT THERAPY; SENTINEL LYMPH NODE BIOPSY; TAXOIDS; TREATMENT OUTCOME;

EID: 84858434008     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.12     Document Type: Review

References (48)

1. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 26(5), 778-785 (2008)
2. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J. Natl Cancer Inst. 97(3), 188-194 (2005
3. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br. J. Surg. 94(10), 1189-1200 (2007
4. Caudle AS, Gonzalez-Angulo AM, Hunt KK et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28(11), 1821-1828 (2010
5. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8), 2672-2685 (1998
6. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16(1), 93-100 (1998
7. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17(2), 460-469 (1999
8. Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur. J. Cancer 47(14), 2084-2090 (2011
9. Jeruss JS, Mittendorf EA, Tucker SL et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J. Clin. Oncol. 26(2), 246-252 (2008
10. Mittendorf EA, Jeruss JS, Tucker SL et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J. Clin. Oncol. 29(15), 1956-1962 (2010
11. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann. Oncol. 10(1), 47-52 (1999
12. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15(7), 2483-2493 (1997
13. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. 2001(30), 96-102 (2001
14. Cochrane RA, Valasiadou P, Wilson AR, Al-Ghazal SK, Macmillan RD. Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br. J. Surg. 90(12), 1505-1509 (2003
15. Buchholz TA, Lehman CD, Harris JR et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A National Cancer Institute conference. J. Clin. Oncol. 26(5), 791-797 (2008
16. van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol. 19(22), 4224-4237 (2001
17. Rouzier R, Mathieu MC, Sideris L et al. Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 101(5), 918-925 (2004
18. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24(7), 1037-1044 (2006
19. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J. Clin. Oncol. 23(1), 41-48 (2005
20. Boughey JC, Peintinger F, Meric-Bernstam F et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann. Surg. 244(3), 464-470 (2006
21. Chen AM, Meric-Bernstam F, Hunt KK et al. Breast conservation after neoadjuvant chemotherapy: The MD Anderson Cancer Center experience. J. Clin. Oncol. 22(12), 2303-2312 (2004
22. Cabioglu N, Hunt KK, Sahin AA et al. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann. Surg. Oncol. 14(4), 1458-1471 (2007
23. Chen AM, Meric-Bernstam F, Hunt KK et al. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4), 689-695 (2005
24. Huang EH, Strom EA, Perkins GH et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 352-357 (2006
25. Akay CL, Meric-Bernstam F, Hunt KK et al. Evaluation of the MD Anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann. Surg. Oncol. doi:10.1245/s10434-011-2006-7 (2011) (Epub ahead of print
26. Mittendorf EA, Buchholz TA, Tucker SL et al. Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy. Presented at: American Society of Clinical Oncology Breast Cancer Symposium. San Francisco, CA, USA, 8-10 September 2011 (Abstract 82
27. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005
28. Ellis MJ. Preoperative endocrine therapy for older women with breast cancer: Renewed interest in an old idea. Cancer Control 7(6), 557-562 (2000
29. Ota DM, Nelson H, Ellis M, Hunt K. Measuring the impact of Z1031 on clinical practice. Bull. Am. Coll. Surg. 96(5), 57-59(2011
30. Ellis MJ, Suman VJ, Hoog J et al. Randomized Phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J. Clin. Oncol. 29(17), 2342-2349 (2011
31. Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23(22), 5108-5116 (2005
32. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann. Oncol. 12(11), 1527-1532 (2001
33. Kuerer HM, Sahin AA, Hunt KK et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann. Surg. 230(1), 72-78 (1999
34. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 21(22), 4165-4174 (2003
35. van Deurzen CH, Vriens BE, Tjan-Heijnen VC et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review. Eur. J. Cancer 45(18), 3124-3130 (2009
36. Xing Y, Foy M, Cox DD et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg. 93(5), 539-546 (2006
37. Nason KS, Anderson BO, Byrd DR et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89(11), 2187-2194 (2000
38. Mamounas EP, Brown A, Anderson S et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 23(12), 2694-2702 (2005
39. Krag DN, Anderson SJ, Julian TB et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP B-32 randomised Phase III trial. Lancet Oncol. 8(10), 881-888 (2007
40. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A metaanalysis. Cancer 106(1), 4-16 (2006
41. Hunt KK, Yi M, Mittendorf EA et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann. Surg. 250(4), 558-566 (2009
42. Krishnamurthy S, Sneige N, Bedi DG et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 95(5), 982-988 (2002
43. Hennessy BT, Hortobagyi GN, Rouzier R et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J. Clin. Oncol. 23(36), 9304-9311 (2005
44. Dominici LS, Negron Gonzalez VM, Buzdar AU et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy withconcurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12), 2884-2889 (2010
45. Shen J, Gilcrease MZ, Babiera GV et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109(7), 1255-1263 (2007
46. Gimbergues P, Abrial C, Durando X et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann. Surg. Oncol. 15(5), 1316-1321 (2008)
47. Classe JM, Bordes V, Campion L et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J. Clin. Oncol. 27(5), 726-732 (2009)
48. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18), 1873-1881 (2011)